NEWS

2020-China's Biomedicine Ushers in the Upsurge of Listing

Release time:

2020-11-20 13:53

Affected by theCOVID-19, global IPO activity slows down in 2020. But this year is a glorious year for China's biomedical companies.

Since 2018, theHong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange has been officially opened for trading. It has brought new vitality to China's capital market and the development of China's technology.. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list.

According to incomplete statistics, as of Nov 20, at least 13 Chinese biopharmaceutical companies have been listed on the HKEx and 10 companies have been listed on the STAR Market. See the table below for details:

 

S/N

Company name

Stock Exchange

Capital Raised

Business area

1

Akeso,Inc

HKEx

Over $300 million

Tumour,Autoimmune Disease

2

Innocent

HKEx

About HK$2.093 billion

Cancer,Autoimmune Disease

3

Kintor Pharmaceutical Limited

HKEx

About $240 million

Prostate Cancer,Breast Cancer

Liver cancer,Baldness

4

Zai Lab Limited

HKEx

HK$5.73 billion

Tumour,Autoimmune Disease

5

Immunotech Biopharm Ltd

HKEx

HK$1.0241 billion

T-Cell Immunotherapy

6

Ocumension Therapeutics

HKEx

HK$1.553 billion

Ophthalmology

7

 

Hepalink

HKEx

HK$3.8 billion

Heparin,Tumour

8

Jhbp (Cy) Holdings Limited

HKEx

-----

Tumour,Autoimmune Disease

9

Everest Medicines Limited

HKEx

-----

Tumour,Autoimmune Disease

Cardiorenal diseases

Infectious disease

10

Simcere Pharmaceutical Group Limited

HKEx

-----

 

Tumour,Central nervous system diseases,Autoimmune Disease

11

Jw (Cayman) Therapeutics Co. Ltd

HKEx

-----

CAR-T

12

Remingling Co. Ltd.

HKEx

-----

Autoimmune Disease,Tumour

Ophthalmology

13

Antengene Corporation Limited

HKEx

-----

Tumour

14

Tells

STAR Market

About ¥2.026 billion

Tumour,Hematopathy

Hepatobiliary disease

15

Bio-Thera Solutions, Ltd

STAR Market

About ¥2.0 billion

Tumour,Autoimmune Disease

16

Sinocelltech Grou Limited

STAR Market

About ¥1.282 billion

Monoclonal Antibody

Recombination Protein,Vaccines

17

HitGen Inc.

STAR Market

About ¥830 million

The lead drug

18

Cansino Biologics Inc.

STAR Market

About ¥5.2 billion

Vaccines

19

Sunshine Guojian Pharmaceutical(shanghai) Co. Ltd.

STAR Market

¥3.183 billion

Antibody

20

Jiangsu Aidea Pharmaceutical Co.,ltd

STAR Market

¥839.4 million

Antidote,Tumour

21

Junshi BiosciencesCo., Ltd.

STAR Market

About ¥2.7 billion

Tumour,Chronic disease

Autoimmune Disease

22

Easton BioPharmaceuticals Co.,Ltd

STAR Market

¥1.335 billion

Combination of generic drug

development

23

Frontier Biotechnologies Inc

STAR Market

¥1.845 billion

AIDS antiviral treatment.

 Pain therapy

In addition to the companies listed in the above table, other biopharmaceutical companies such as Beijing Science Sun Pharmaceutical Co.,LTD,Changchun BCHT Biotechnology Co and other companies have also submitted IPO applications to theHKEx and theSTAR Market

The,hkex,star,market,billion,disease,tumour,yen,autoimmune